Polymyxin B-immobilized fiber column hemoperfusion therapy for septic shock

Shock

Volumn 36, Issue 4, 2011, Pages 332-338

  Mitaka, Chieko ^a   Tomita, Makoto ^b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

Endotoxin; hemodynamics; hemoperfusion; LPS; polymyxin B; sepsis; septic shock

Indexed keywords

ANANDAMIDE; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTOXIN; INOTROPIC AGENT; INTERCELLULAR ADHESION MOLECULE 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMYXIN B;

APOPTOSIS; ARTICLE; BLOOD PRESSURE; CHEMICAL PHENOMENA; CONTROLLED STUDY; COVALENT BOND; DRUG EFFICACY; DRUG MECHANISM; EXTRACORPOREAL OXYGENATION; FIBER; HEMODYNAMICS; HEMOPERFUSION; HUMAN; HYDRODYNAMICS; HYDROPHOBICITY; IMMOBILIZATION; IMMUNOSUPPRESSIVE TREATMENT; MEDLINE; META ANALYSIS; MONOCYTE; MORTALITY; NEUTROPHIL; PROTEIN BLOOD LEVEL; SEPTIC SHOCK; SYSTEMATIC REVIEW;

ANTI-BACTERIAL AGENTS; ENDOTOXINS; HEMODYNAMICS; HEMOPERFUSION; HUMANS; POLYMYXIN B; SHOCK, SEPTIC;

EID: 80052969364     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0b013e318225f839     Document Type: Article

References (50)

1. Peters K, Unger RE, Brunner J, Kirkpatrick CJ: Molecular basis of endothelial dysfunction in sepsis. Cardiovasc Res 60(1):49-57, 2003. (Pubitemid 38373475)
2. Shoji H: Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial 7(1):108-114, 2003. (Pubitemid 36648053)
3. Aoki H, Kodama M, Tani T, Hanasawa K: Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B immobilized fiber. Am J Surg 167(4):412-417, 1994.
4. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20(6): 864-874, 1992.
5. Nakamura T, Ebihara I, Shoji H, Ushiyama C, Suzuki S, Koide H: Treatment with polymyxin BYimmobilized fiber reduces platelet activation in septic shock patients: decrease in plasma levels of soluble P-selectine, platelet factor 4 and "-thromboglobulin. Inflamm Res 48(4):171-175, 1999. (Pubitemid 29192518)
6. Nemoto H, Nakamoto H, Okada H, Sugahara S, Moriwaki K, Arai M, Kanno Y, Suzuki H: Newly developed immobilized polymyxin B fibers improve the survival of patients with sepsis. Blood Purif 19:361-369, 2001. (Pubitemid 34701465)
7. Nakamura T, Matsuda T, Suzuki Y, Shoji H, Koide H: Polymyxin BYimmobilized fiber hemoperfusion in patients with sepsis. Dial Transplant 32(10):602-607, 2003.
8. Nakamura T, Kawagoe Y, Matsuda T, Koide H: Effect of polymyxin BYimmobilized fiber on bone resorption in patients with sepsis. Intensive Care Med 30(9):1838-1841, 2004. (Pubitemid 39297191)
9. Vincent JL, Laterre PF, Cohen J, Burchardi H, Bruining H, Lerma FA, Wittebole X, De Backer D, Brett S, Marzo D, et al.: A pilot-controlled study of a polymyxin BYimmobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 23(5):400-405, 2005. (Pubitemid 40571661)
10. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Pallavicini FMB, et al.: Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 301(23):2445-2452, 2009.
11. Nakamura T, Ushiyama C, Shoji H, Koide H: Effects of hemoperfusion on serum cardiac troponin T concentrations using polymyxin BYimmobilized fibers in septic patients undergoing hemodialysis. ASAIO Journal 48:41-44, 2002. (Pubitemid 34575768)
12. Suzuki H, Nemoto H, Nakamoto H, Okada H, Sugawara S, Kanno Y, Moriwaki K: Continuous hemodiafiltration with polymyxin BYimmobilized fiber is effective in patients with sepsis syndrome and acute renal failure. Ther Apher 6(3):234-240, 2002. (Pubitemid 34753568)
13. Tani T, Hanasawa K, Kodama M, Imaizumi H, Yonekawa M, Saito M, Ikeda T, Yagi Y, Takayama K, Amano I, et al.: Correlation between plasma endotoxin, plasma cytokines, and plasminogen activator inhibitor-1 activities in septic shock patients. World J Surg 25(5):660-668, 2001. (Pubitemid 32441443)
14. Ikeda T, Ikeda K, Nagura M, Taniuchi H, Matsushita M, Kiuchi S, Kuroki Y, Suzuki K, Matsuno N: Clinical evaluation of PMX-DHP for hypercytokinemia caused by septic multiple organ failure. Ther Apher Dial 8(4):293-298, 2004. (Pubitemid 39108746)
15. Ono S, Tsujinomoto H, Matsumoto A, Ikuta S, Kinoshita M, Mochizuki H: Modulation of human leukocyte antigen-DR on monocytes and CD16 on granulocytes in patients with septic shock using hemoperfusion with polymyxin BYimmobilized fiber. Am J Surg 188:150-156, 2004. (Pubitemid 38916733)
16. Kushi H, Miki T, Okamoto K, Nakahara J, Saito T, Tanjoh K: Early hemoperfusion with an immobilized polymyxin B fiber column eliminates humoral mediators and improves pulmonary oxygenation. Crit Care 9:R653-R661, 2005.
17. Mitaka C, Tsuchida N, Kawada K, Nakajima Y, Imai T, Sasaki S: A longer duration of polymyxin BYimmobilized fiber column hemoperfusion improves pulmonary oxygenation in patients with septic shock. Shock 32(5):478-483, 2009.
18. Ueno T, Ikeda T, Ikeda K, Taniuchi H, Suda S, Yeung MY, Matsuno N: HMGB-1 as a useful prognostic biomarker in sepsis-induced organ failure in patients undergoing PMX-DHP. J Surg Res 2009 Dec 10 [ePub ahead of print].
19. Novelli G, Ferretti G, Poli L, Pretagostini R, Ruberto F, Perrella SM, Levi S, Morabito V, Berloco PB: Clinical results of treatment of postsurgical endotoxinmediated sepsis with polymyxin-B direct hemoperfusion. Transplant Proc 42(4): 1021-1024, 2010.
20. Kumagai T, Takeyama N, Yabuki T, Harada M, Miki Y, Kanou H, Inoue S, Nakagawa T, Noguchi H: Apheresis of activated leukocytes with an immobilized polymyxin B filter in patients with septic shock. Shock 34(5):461-466, 2010.
21. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Maeda S, Yamagishi S: Suppression of high-mobility group box-1 and receptor for advanced glycation end-product axis by polymixin B-immobilized fiber hemoperfusion in septic shock patients [published online ahead of print]. J Crit Care 2011 Jan 25 [ePub ahead of print].
22. Kojika M, Sato N, Yaegashi Y, Suzuki Y, Suzuki K, Nakae H, Endo S: Endotoxin adsorption therapy for septic shock using polymyxin BYimmobilized fibers (PMX): evaluation by high-sensitivity endotoxin assay and measurement of the cytokine production capacity. Ther Apher Dial 10(1):12-18, 2006.
23. Oishi H, Takaoka A, Hatayama Y, Matsuo T, Sakata Y: Automated limulus amebocyte lysate (LAL) test for endotoxin analysis using a new toxinometer ET-201. J Parenter Sci Technol 39(5):194-200, 1985. (Pubitemid 16191785)
24. Kambayashi J, Yokota M, Sakon M, Shiba E, Kawasaki T, Mori T, Tsuchiya M, Oishi H, Matsuura S: A novel endotoxin-specific assay by turbidimetry with limulus amoebocyte lysate containing "-glucan. J Biochem Biophys Methods 22:93-100, 1991.
25. Kushi H, Miki T, Nakahara J, Okamoto K, Saito T, Tanjoh K: Hemoperfusion with an immobilized polymyxin B column reduces the blood level of neutrophil elastase. Blood Purif 24(2):212-217, 2006. (Pubitemid 43259176)
26. Nakamura T, Ebihara I, Shimada N, Koide H: Changes in plasma erythropoietin and interleukin-6 concentrations in patients with septic shock after hemoperfusion with polymyxin BYimmobilized fiber. Intensive Care Med 24(12):1272-1276, 1998. (Pubitemid 28564449)
27. Nakamura T, Kawagoe Y, Matsuda T, Shoji H, Ueda Y, Tamura N, Ebihara I, Koide H: Effect of polymyxin BYimmobilized fiber on blood metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 levels in acute respiratory distress syndrome patients. Blood Purif 22(3):256-260, 2004. (Pubitemid 39177729)
28. Wang Y, Liu Y, Sarker KP, Nakashima M, Serizawa T, Kishida A, Akashi M, Nakata M, Kitajima I, Maruyama I: Polymyxin B binds to anandamide and inhibits its cytotoxic effect. FEBS Lett 470(2):151-155, 2000. (Pubitemid 30151087)
29. Fernandes CJ Jr, Akamine N, Knobel H: Cardiac troponin: a new serum marker of myocardial injury in sepsis. Intensive Care Med 25(10):1165-1168, 1999. (Pubitemid 29525077)
30. Moncada S, Higgs A: The L-arginine nitric oxide pathway. N Engl J Med 329:2002-2012, 1993.
31. Tsujimoto H, Ono S, Hiraki S, Majima T, Kawarabayashi N, Sugasawa H, Kinoshita M, Hiraide H, Mochizuki H: Hemoperfusion with polymyxin BYimmobilized fibers reduced the number of CD16+CD14+ monocytes in patients with septic shock. J Endotoxin Res 10(4):229-237, 2004. (Pubitemid 39481012)
32. Nishibori M, Takahashi HK, Katayama H, Mori S, Saito S, Iwagaki H, Tanaka N, Morita K, Ohtsuka A: Specific removal of monocytes from peripheral blood of septic patients by polymyxin BYimmobilized filter column. Acta Med Okayama 63(1):65-69, 2009.
33. Cantaluppi V, Assenzio B, Pasero D, Romanazzi GM, Pacitti A, Lanfranco G, Puntorieri V, Martin EL, Mascia L, Monti G, et al.: Polymyxin-B hemoperfusion inactivates circulating proapoptotic factors. Intensive Care Med 34(9):1638-1643, 2008.
34. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, et al.: HMG-1 as a late mediator of endotoxin lethality in mice. Science 285(5425):248-251, 1999. (Pubitemid 29329996)
35. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A: HMGB-1: endogenous danger signaling. Mol Med 14(7-8):476-484, 2008.
36. Vesentini S, Sonicini M, Zaupa A, Silvestri V, Fiore GB, Redaelli A: Multiscale analysis of the Toraymyxin adsorption cartridge. Part I: molecular interaction of polymyxin B with endotoxins. Int J Artif Organs 29(2):239-250, 2006.
37. Fiore GB, Soncicni M, Vesentini S, Penati A, Visconti G, Redaelli A: Multiscale analysis of the Toraymyxin adsorption cartridge. Part II: computational fluid-dynamic study. Int J Artif Organs 29(2):251-260, 2006.
38. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR: The CHESS Trial Study Group: treatment of septic shock with human monoclonal antibody HA-1A. A randomized double-blind, placebo-controlled trial. Ann Intern Med 121:1-5, 1994.
39. Angus DC, Birmingham MC, Balk RA, Scannon PJ, Collins D, Kruse JA, Graham DR, Dedhia HV, Homann S, MacIntyre N: The E5 Study Investigators. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. JAMA 283: 1723-1730, 2000. (Pubitemid 30196213)
40. Dellinger RP, Tomayko JF, Angus DC, Opal S, Cupo MA, McDermott S, Ducher A, Calandra T, Cohen J: The Lipid Infusion and Patient Outcomes in Sepsis (LIPOS) Investigators. Efficacy and safety of a phospholipid emulsion (GR270773) in gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial. Crit Care Med 37:2929-2938, 2009.
41. Tidswell M, Tillis W, LaRosa SP, Lynn M, Wittek AE, Kao R, Wheeler J, Gogate J, Opal SM: The Eritoran Sepsis Study Group. Phase 2 trial eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med 38:72-83, 2010.
42. Opal SM, Glück T: Endotoxin as a drug target. Crit Care Med 21(Suppl): S54-S64, 2003.
43. Ronco C: The immunomodulatory effect of extracorporeal therapies in sepsis: a reconciliation of three theories. Int J Artif Organs 30:855-857, 2007.
44. Shenep JL, Flynn PM, Barrett FF, Stidham GL, Westenkirchner DF: Serial quantification of endotoxemia and bacteremia during therapy for gram-negative bacterial sepsis. J Infect Dis 157(3):565-568, 1988. (Pubitemid 18071457)
45. Takeshita S, Nakatani K, Tsujimoto H, Kawamura Y, Sekine I: Detection of circulating lipopolysaccharide-bound monocytes in children with gramnegative sepsis. J Infect Dis 182:1549-1552, 2000.
46. Pöschl JM, Leray C, Ruef P, Cazenave JP, Linderkamp O: Endotoxin binding to erythrocyte membrane and erythrocyte deformability in human sepsis and in vitro. Crit Care Med 31:924-928, 2003. (Pubitemid 36379605)
47. Salden HJM, Bas BM: Endotoxin binding to platelets in blood from patients with a sepsis syndrome. Clin Chem 40(8):1575-1579, 1994. (Pubitemid 24241142)
48. Spielvogel AR: An ultrastructural study of the mechanisms of plateletendotoxin interaction. J Exp Med 126:235-250, 1967.
49. Banoub JH, Aneed AEI, Cohen AM, Joly N: Structural investigation of bacterial lipopolysaccharides by mass spectrometry and tandem mass spectrometry. Mass Spectrom Rev 29:606, 2010.
50. Gunn JS, Lim KB, Krueger J, Kim K, Guo L, Hackett M, Miller SI: PmrAPmrBYregulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance. Mol Microbiol 27(6):1171-1182, 1998. (Pubitemid 28137969)